NCT03127124 is a Phase 1, PHASE2 clinical trial of NANT-008 in Pancreatic Adenocarcinoma Metastatic, sponsored by NantPharma, LLC.

Who is sponsoring NCT03127124?

NCT03127124 is sponsored by NantPharma, LLC.

What drugs are being tested in NCT03127124?

Interventions in NCT03127124: NANT-008, Fluorouracil Injectable Product, Avastin Injectable Product, Leucovorin Calcium Injection, Eloxatin Injectable Product.

What condition does NCT03127124 study?

NCT03127124 studies Pancreatic Adenocarcinoma Metastatic.

Is NCT03127124 still recruiting?

NCT03127124 is currently withdrawn. Last updated 2 April 2024.

Last reviewed 2024-04-02 · How we verify

NCT03127124

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer

Withdrawn Phase 1, PHASE2 Last updated 2 April 2024

What this trial tests

Phase 1, PHASE2 trial testing NANT-008 in Pancreatic Adenocarcinoma Metastatic. Withdrawn.

Timeline

27 February 2018

Primary endpoint
6 December 2023

6 December 2023

Quick facts

Lead sponsor	NantPharma, LLC
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	27 February 2018
Primary completion	6 December 2023
Estimated completion	6 December 2023
Sites	1 location across United States

Drugs / interventions tested

NANT-008 — full drug profile →
Fluorouracil Injectable Product — full drug profile →
Avastin Injectable Product — full drug profile →
Leucovorin Calcium Injection
Eloxatin Injectable Product — full drug profile →

Conditions studied

Pancreatic Adenocarcinoma Metastatic — all drugs for Pancreatic Adenocarcinoma Metastatic →

Sponsor

NantPharma, LLC — full company profile →

Who can join

Adults 18 to 65, any sex, with Pancreatic Adenocarcinoma Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1b/2 study to evaluate the safety and efficacy of NANT-008 in combination with 5-fluorouracil, bevacizumab, leucovorin, and oxaliplatin in patients with metastatic pancreatic adenocarcinoma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

TAMing pancreatic cancer: combat with a double edged sword.
Lankadasari MB, Mukhopadhyay P, Mohammed S, Harikumar KB. · · 2019 · cited 84× · PMID 30925924 · DOI 10.1186/s12943-019-0966-6
Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance.
Deng D, Patel R, Chiang CY, Hou P. · · 2022 · cited 37× · PMID 36230914 · DOI 10.3390/cells11192952
Challenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment.
Finan JM, Guo Y, Goodyear SM, Brody JR. · · 2024 · cited 9× · PMID 39735733 · DOI 10.1200/oa-24-00050

Verify or expand the search:

Other recruiting trials for Pancreatic Adenocarcinoma Metastatic

Currently open trials in the same condition.

NCT06396637 — PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC · Phase 2 · recruiting
NCT06792435 — XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. · Phase 1, PHASE2 · recruiting
NCT06051851 — Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic P · Phase 2 · recruiting
NCT05077800 — FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer · Phase 2 · active not recruiting

Other NantPharma, LLC trials

Trials by the same sponsor.

NCT03132155 — QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma · Phase 2 · terminated
NCT03147976 — QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors · Phase 2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03127124 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NantPharma, LLC
Last refreshed: 2 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03127124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing